Oric Pharmaceuticals Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hey, everyone. Thanks for joining us this afternoon. I am here with ORIC Pharmaceuticals. I have CFO, Dom, and Matt, CBO. It has been quite a year for PRC2. I think we have all been waiting for this MEVPRO-1 data set that has continuously gotten pushed out. Maybe a good place to start is, I guess, a brief introduction to the company. Then my first question will be, how are you guys reading this Pfizer push-out of MEVPRO-1?
Yeah. First of all, thank you for having us here at the conference. At a high level, ORIC is a clinical-stage oncology company. Our name really encapsulates our mission, which is to overcome resistance in cancer. We have got two late-stage clinical programs. The first one is rinzimetostat. This is an allosteric PRC2 inhibitor that we are studying in prostate cancer in combination with AR inhibitors. We initiated our first phase III study early this year, which is known as Himalayas-1, and that timeline, we are expecting top-line data in the first half of 2028. The second program, enozertinib, this is an EGFR TKI that we are studying in two distinct patient populations in non-small cell lung cancer, both EGFR atypical and EGFR exon 20.
We did present some data at ESMO earlier this year, which we will talk about, and then we will have some additional data in the exon 20 patient population mid-2027 as well. We are looking to start our first phase III study on the atypical patient population in the first half of next year. Looking forward to next year, we should have two ongoing phase III studies.
I think this is the first time I have ever heard you say we have two late-stage- Yeah companies.
Yeah. Studies going on. So, as has become expected, let's talk about MEVPRO-1, which is actually not our drug, it's Pfizer's drug.
I guess taking a step back in our view on kind of the timeline shifts from Pfizer, I think taking a big step back is, first and foremost, there's been a lot of data sets recently from Pfizer, from other competitors, as well as ourselves, that has shown the benefit of combining a PRC2 inhibitor with an AR inhibitor. I think the most compelling data set that we've seen, obviously, is the randomized data we saw from Pfizer back at ASCO 2025. This is an 80-patient study. It was a randomized study. The treatment arm showed a 14.3-month benefit, PFS benefit. The control arm showed about a six-month benefit. So pretty profound results in this patient population. This is post-abiraterone patients that could have seen up to one round of chemo.
From a high level, this is highly validated from a biological standpoint. Pfizer started their study, MEVPRO-1, which is in its exact patient population. It's a 600-patient study. They're showing the combination of mevrometostat, I should say, in combination with enzalutamide versus a control arm, a physician's choice between AR inhibitor and docetaxel. They started this in late 2024. They had originally had their primary completion date as of, call it, mid-2026, so I think we were expecting it around that time. Since that, on their Q2 earnings call in early August, they shifted that guidance to Q4 of this year. On their Q3 earnings call, they just shifted it again to first quarter of next year. I think they said February of 2027. At a high level, obviously, it's a blinded study. We don't know any more than you guys do.
But as you guys can imagine, a number of these street analysts, investors, as well as ourselves, we have done a lot of event-based modeling to try to predict what the potential scenarios are relating to this delay. At a high level, we kind of looked at this in four quadrants, right? The big miss scenario, the slight miss, the slight win, and the big win. I think based on, again, all the data that we have seen so far with this mechanism, based on the event modeling we have done, I think we feel pretty comfortable that that big miss is very low probability, if not off the table. So there is always a possibility of a small miss, and obviously, we do not know what that would be. We think, again, the biology makes a lot of sense.
So if there is a miss, maybe it is regimen-related, maybe it has something to do with their safety profile or high discontinuation rates. But in the scenario there is a small win or a big win where the study is positive, obviously, we think that is a strong validation for the mechanism, kind of a read-through to rinzimetostat as well.
Yeah, I mean, just to contextualize a little bit what the control arm could be capable in a study like this. You have ARPI switching, you have chemo. It does not seem like anything in the control arm would warrant maybe six to eight months. Do you think that is a fair assumption?
Yeah. I think if you look at the, again, the control arm, just to clarify, is AR, is enzalutamide or docetaxel. So if you look at kind of the benchmarks out there, I think you will see docetaxel in this patient population will be, as you said, like seven to eight months. The AR inhibitor in the post-abiraterone setting will probably give you five to six months. We do not know what that distribution is. Assuming a 50/50 split, that gets you close to 6.75 or 7 months of durability. Could that inch up a little bit? That is possible as well. But we think kind of an outlier there would be unusual. Pfizer has said, I think on their Q2 earnings call, they kind of said they expect the control arm to be somewhere in the five to eight month range.
Obviously, they are closest to the data. That is kind of the latest data that we have.
Yeah. Matt, anything else you would add to that?
No, I think just the study has been delayed, so I think there is obviously multiple ways you could look at that. I think in general, people have gotten comfortable that might be a good signal. I think that is kind of what Pfizer is signaling. That is the way we interpret it as well. I think just because the control arm of docetaxel ARPI switching has been so well studied in phase III studies, and it has been replicated in multiple studies by different parties, that I think people generally feel good that enzalutamide switch should give you about a five to six month- Yeah rPFS.
Docetaxel in multiple phase III studies should give you seven to eight. Anything within that range, I think Pfizer has signaled that is their expectation as well.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
